Real-time enrollment status for this recurrent diffuse hemispheric glioma, h3 g34-mutant clinical trial
Current Status
Recruiting
Checked: October 16, 2026 at 9:29 AM UTC
| NCT Number | NCT06914479 |
| Recruiting Status | Recruiting |
| Condition | Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant |
| Phase | PHASE1 |
| Target Enrollment | 11 participants |
| Active Locations | 1 sites in the US |
| Sponsor | University of Michigan Rogel Cancer Center |
| Last Updated on CT.gov | June 15, 2026 (Jun 15, 2026) |
As of October 16, 2026: Clinical trial NCT06914479 is currently recruiting participants. This phase1 study for recurrent diffuse hemispheric glioma, h3 g34-mutant is actively seeking new participants at 1 location across the United States. The study is sponsored by University of Michigan Rogel Cancer Center. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT06914479 is actively recruiting participants as of October 16, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 1 location in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT06914479 was last updated Jun 15, 2026 (June 15, 2026). HelloStudys verifies this status automatically.